Literature DB >> 6210638

Cryptococcal capsular polysaccharide-induced modulation of murine immune responses.

J F Breen, I C Lee, F R Vogel, H Friedman.   

Abstract

Cryptococcus neoformans, an opportunistic fungal pathogen, often causes serious and life-threatening infections in immunocompromised hosts as well as in normal individuals. In the present study, purified cryptococcal capsular polysaccharide antigen was examined for its effect on several parameters of immune response and its ability to induce immune response to itself. Injection of the antigen into mice resulted in a dose-related specific antibody response which was detected at the individual antibody plaque-forming-cell level by a hemolytic assay in gel. Relatively low doses of cryptococci induced a maximal response, whereas higher doses resulted in a markedly depressed response. The antibody response to the cryptococcal capsular polysaccharide antigen appeared to be T cell independent and regulated by suppressor T cells, since mice injected with antilymphocyte serum or antithymocyte serum showed specific antibody responses to the antigen that were higher than those of untreated mice. It also markedly affected the in vitro mixed-lymphocyte reaction when added to cultures of mouse spleen cells being challenged in vitro with mitomycin C-treated allogeneic cells. The lower doses stimulated the response, whereas higher doses suppressed it. The macrophage response to yeast cells but not opsonized sheep erythrocytes was also modulated by the cryptococcal antigen.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 6210638      PMCID: PMC351182          DOI: 10.1128/iai.36.1.47-51.1982

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  14 in total

1.  Factors influencing killing of Cryptococcus neoformans by human leukocytes in vitro.

Authors:  R D Diamond; R K Root; J E Bennett
Journal:  J Infect Dis       Date:  1972-04       Impact factor: 5.226

2.  Cell-mediated immunity in Cryptococcosis.

Authors:  J R Graybill; R H Alford
Journal:  Cell Immunol       Date:  1974-10       Impact factor: 4.868

3.  Evidence for the existence of two functionally distinct types of cells which regulate the antibody response to type 3 pneumococcal polysaccharide.

Authors:  P J Baker; P W Stashak; D F Amsbaugh; B Prescott; R F Barth
Journal:  J Immunol       Date:  1970-12       Impact factor: 5.422

4.  Characterization of the antibody response to type 3 pneumococcal polysaccharide at the cellular level. I. Dose-response studies and the effect of prior immunization on the magnitude of the antibody response.

Authors:  P J Baker; P W Stashak; D F Amsbaugh; B Prescott
Journal:  Immunology       Date:  1971-04       Impact factor: 7.397

5.  Further improvements in the plaque technique for detecting single antibody-forming cells.

Authors:  A J Cunningham; A Szenberg
Journal:  Immunology       Date:  1968-04       Impact factor: 7.397

6.  Abnormalities in cell-mediated immunity in patients with Cryptococcus neoformans infection.

Authors:  S C Schimpff; J E Bennett
Journal:  J Allergy Clin Immunol       Date:  1975-06       Impact factor: 10.793

7.  Inhibition of phagocytosis by cryptococcal polysaccharide: dissociation of the attachment and ingestion phases of phagocytosis.

Authors:  T R Kozel; R P Mastroianni
Journal:  Infect Immun       Date:  1976-07       Impact factor: 3.441

8.  Strain differences in the ability of antithymocyte serum (ATS) to enhance the antibody response of inbred mice to type 3 pneumococcal polysaccharide.

Authors:  D R Barthold; P W Stashak; D F Amsbaugh; B Prescott; P J Baker
Journal:  Cell Immunol       Date:  1973-02       Impact factor: 4.868

9.  Immune response to Cryptococcus neoformans soluble polysaccharide: immunological unresponsiveness.

Authors:  T R Kozel; W F Gulley; J Cazin
Journal:  Infect Immun       Date:  1977-12       Impact factor: 3.441

10.  Immunological unresponsiveness induced by cryptococcal capsular polysaccharide assayed by the hemolytic plaque technique.

Authors:  J W Murphy; G C Cozad
Journal:  Infect Immun       Date:  1972-06       Impact factor: 3.441

View more
  23 in total

1.  Production and characterization of monoclonal antibodies specific for Cryptococcus neoformans capsular polysaccharide.

Authors:  T F Eckert; T R Kozel
Journal:  Infect Immun       Date:  1987-08       Impact factor: 3.441

2.  Genetic control of the humoral response to cryptococcal capsular polysaccharide in mice.

Authors:  F Dromer; P Yeni; J Charreire
Journal:  Immunogenetics       Date:  1988       Impact factor: 2.846

3.  Induction of a macrophage-suppressive lymphokine by soluble cryptococcal antigens and its association with models of immunologic tolerance.

Authors:  R Blackstock; J M McCormack; N K Hall
Journal:  Infect Immun       Date:  1987-01       Impact factor: 3.441

Review 4.  Virulence factors of medically important fungi.

Authors:  L H Hogan; B S Klein; S M Levitz
Journal:  Clin Microbiol Rev       Date:  1996-10       Impact factor: 26.132

5.  Galactoxylomannans of Cryptococcus neoformans.

Authors:  P G James; R Cherniak
Journal:  Infect Immun       Date:  1992-03       Impact factor: 3.441

6.  Binding of purified and radioiodinated capsular polysaccharides from Cryptococcus neoformans serotype A strains to capsule-free mutants.

Authors:  J M Small; T G Mitchell
Journal:  Infect Immun       Date:  1986-12       Impact factor: 3.441

Review 7.  An overview of macrophage-fungal interactions.

Authors:  R A Fromtling; H J Shadomy
Journal:  Mycopathologia       Date:  1986-02       Impact factor: 2.574

8.  Encapsulation of Cryptococcus neoformans impairs antigen-specific T-cell responses.

Authors:  H L Collins; G J Bancroft
Journal:  Infect Immun       Date:  1991-11       Impact factor: 3.441

Review 9.  Polysaccharide antigens of the capsule of Cryptococcus neoformans.

Authors:  R Cherniak; J B Sundstrom
Journal:  Infect Immun       Date:  1994-05       Impact factor: 3.441

10.  T-cell-dependent and T-cell-independent mechanisms of tolerance to glucuronoxylomannan of Cryptococcus neoformans serotype A.

Authors:  J B Sundstrom; R Cherniak
Journal:  Infect Immun       Date:  1993-04       Impact factor: 3.441

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.